menu
    • menu
    [{"orgOrder":0,"company":"Cellvera","sponsor":"Aditxt","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.A.E","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Favipiravir","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cellvera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cellvera \/ Aditxt","highestDevelopmentStatusID":"15","companyTruncated":"Cellvera \/ Aditxt"}]

    Find Clinical Drug Pipeline Developments & Deals by Cellvera

    Menu

    Cellvera

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Cellvera

    U.A.E arrow
    Peptide Therapy Summit
    Not Confirmed

    Cellvera

    U.A.E arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Favipiravir

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Approved FDF

    Sponsor : Aditxt

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Aditxt Signs Revenue-Sharing Agreement with Cellvera for up to $30M, and Hosts a Live Business Update Webinar ...

    Details : Cellvera holds worldwide rights (except Japan) to a broad spectrum oral antiviral drug targeting COVID-19 and other infectious diseases. Cellvera is focused on developing and commercializing antimicrobial therapies across a broad spectrum infectious dise...

    Product Name : Avigan

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    May 04, 2022

    Lead Product(s) : Favipiravir

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved FDF

    Sponsor : Aditxt

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth